Progressive muscle relaxation therapy for atopic dermatitis

Objective assessment of efficacy

Byung Gi Bae, SangHo Oh, Chang Ook Park, Seongmin Noh, Ji Yeon Noh, Kyung Ran Kim, Kwanghoon Lee

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The aims of this study were to validate the efficacy of progressive muscle relaxation (PMR) in patients with atopic dermatitis and to evaluate the serological parameters that may serve as objective measures of the efficacy of PMR. A total of 25 patients with atopic dermatitis were randomly assigned to either a PMR group (n = 15) or a control group (n = 10). Serum levels of nerve growth, neuropeptide Y, and Th2 cytokines (IL-4, IL-5, and IL- 13) were measured at baseline and after one month. At baseline, only anxiety was positively correlated with pruritus score (state anxiety: R = 0.496, p = 0.014; trait anxiety: R = 0.423, p = 0.04). Serum levels of neuropeptide Y were inversely related to the State-Trait Anxiety Inventory (STAI) (state anxiety: R = -0.475, p = 0.019; trait anxiety: R = -0.418, p = 0.042) and pruritus scores (R = -0.451, p = 0.035). After one month of PMR therapy, the degree of pruritus and loss of sleep was significantly decreased in the PMR group (p < 0.001), but not among controls. State anxiety scores showed significant improvement after treatment only in the PMR group (p = 0.005). There were no significant changes in the serological parameters in either group. Reductions in Eczema Area and Severity Index (EASI) scores were significant, but similar, in both groups. PMR may be a useful adjunctive modality for the management of atopic dermatitis through the reduction of anxiety. No change was found in biological parameters, but it was observed that neuropeptide Y may be related to high levels of anxiety in atopic dermatitis at baseline.

Original languageEnglish
Pages (from-to)57-61
Number of pages5
JournalActa Dermato-Venereologica
Volume92
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Autogenic Training
Relaxation Therapy
Atopic Dermatitis
Anxiety
Neuropeptide Y
Pruritus
Interleukin-13
Eczema
Interleukin-5
Serum
Interleukin-4
Sleep
Cytokines

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Bae, Byung Gi ; Oh, SangHo ; Park, Chang Ook ; Noh, Seongmin ; Noh, Ji Yeon ; Kim, Kyung Ran ; Lee, Kwanghoon. / Progressive muscle relaxation therapy for atopic dermatitis : Objective assessment of efficacy. In: Acta Dermato-Venereologica. 2012 ; Vol. 92, No. 1. pp. 57-61.
@article{0a59137389e5416bb2138c5f6f8ccfbe,
title = "Progressive muscle relaxation therapy for atopic dermatitis: Objective assessment of efficacy",
abstract = "The aims of this study were to validate the efficacy of progressive muscle relaxation (PMR) in patients with atopic dermatitis and to evaluate the serological parameters that may serve as objective measures of the efficacy of PMR. A total of 25 patients with atopic dermatitis were randomly assigned to either a PMR group (n = 15) or a control group (n = 10). Serum levels of nerve growth, neuropeptide Y, and Th2 cytokines (IL-4, IL-5, and IL- 13) were measured at baseline and after one month. At baseline, only anxiety was positively correlated with pruritus score (state anxiety: R = 0.496, p = 0.014; trait anxiety: R = 0.423, p = 0.04). Serum levels of neuropeptide Y were inversely related to the State-Trait Anxiety Inventory (STAI) (state anxiety: R = -0.475, p = 0.019; trait anxiety: R = -0.418, p = 0.042) and pruritus scores (R = -0.451, p = 0.035). After one month of PMR therapy, the degree of pruritus and loss of sleep was significantly decreased in the PMR group (p < 0.001), but not among controls. State anxiety scores showed significant improvement after treatment only in the PMR group (p = 0.005). There were no significant changes in the serological parameters in either group. Reductions in Eczema Area and Severity Index (EASI) scores were significant, but similar, in both groups. PMR may be a useful adjunctive modality for the management of atopic dermatitis through the reduction of anxiety. No change was found in biological parameters, but it was observed that neuropeptide Y may be related to high levels of anxiety in atopic dermatitis at baseline.",
author = "Bae, {Byung Gi} and SangHo Oh and Park, {Chang Ook} and Seongmin Noh and Noh, {Ji Yeon} and Kim, {Kyung Ran} and Kwanghoon Lee",
year = "2012",
month = "1",
day = "1",
doi = "10.2340/00015555-1189",
language = "English",
volume = "92",
pages = "57--61",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "1",

}

Progressive muscle relaxation therapy for atopic dermatitis : Objective assessment of efficacy. / Bae, Byung Gi; Oh, SangHo; Park, Chang Ook; Noh, Seongmin; Noh, Ji Yeon; Kim, Kyung Ran; Lee, Kwanghoon.

In: Acta Dermato-Venereologica, Vol. 92, No. 1, 01.01.2012, p. 57-61.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Progressive muscle relaxation therapy for atopic dermatitis

T2 - Objective assessment of efficacy

AU - Bae, Byung Gi

AU - Oh, SangHo

AU - Park, Chang Ook

AU - Noh, Seongmin

AU - Noh, Ji Yeon

AU - Kim, Kyung Ran

AU - Lee, Kwanghoon

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The aims of this study were to validate the efficacy of progressive muscle relaxation (PMR) in patients with atopic dermatitis and to evaluate the serological parameters that may serve as objective measures of the efficacy of PMR. A total of 25 patients with atopic dermatitis were randomly assigned to either a PMR group (n = 15) or a control group (n = 10). Serum levels of nerve growth, neuropeptide Y, and Th2 cytokines (IL-4, IL-5, and IL- 13) were measured at baseline and after one month. At baseline, only anxiety was positively correlated with pruritus score (state anxiety: R = 0.496, p = 0.014; trait anxiety: R = 0.423, p = 0.04). Serum levels of neuropeptide Y were inversely related to the State-Trait Anxiety Inventory (STAI) (state anxiety: R = -0.475, p = 0.019; trait anxiety: R = -0.418, p = 0.042) and pruritus scores (R = -0.451, p = 0.035). After one month of PMR therapy, the degree of pruritus and loss of sleep was significantly decreased in the PMR group (p < 0.001), but not among controls. State anxiety scores showed significant improvement after treatment only in the PMR group (p = 0.005). There were no significant changes in the serological parameters in either group. Reductions in Eczema Area and Severity Index (EASI) scores were significant, but similar, in both groups. PMR may be a useful adjunctive modality for the management of atopic dermatitis through the reduction of anxiety. No change was found in biological parameters, but it was observed that neuropeptide Y may be related to high levels of anxiety in atopic dermatitis at baseline.

AB - The aims of this study were to validate the efficacy of progressive muscle relaxation (PMR) in patients with atopic dermatitis and to evaluate the serological parameters that may serve as objective measures of the efficacy of PMR. A total of 25 patients with atopic dermatitis were randomly assigned to either a PMR group (n = 15) or a control group (n = 10). Serum levels of nerve growth, neuropeptide Y, and Th2 cytokines (IL-4, IL-5, and IL- 13) were measured at baseline and after one month. At baseline, only anxiety was positively correlated with pruritus score (state anxiety: R = 0.496, p = 0.014; trait anxiety: R = 0.423, p = 0.04). Serum levels of neuropeptide Y were inversely related to the State-Trait Anxiety Inventory (STAI) (state anxiety: R = -0.475, p = 0.019; trait anxiety: R = -0.418, p = 0.042) and pruritus scores (R = -0.451, p = 0.035). After one month of PMR therapy, the degree of pruritus and loss of sleep was significantly decreased in the PMR group (p < 0.001), but not among controls. State anxiety scores showed significant improvement after treatment only in the PMR group (p = 0.005). There were no significant changes in the serological parameters in either group. Reductions in Eczema Area and Severity Index (EASI) scores were significant, but similar, in both groups. PMR may be a useful adjunctive modality for the management of atopic dermatitis through the reduction of anxiety. No change was found in biological parameters, but it was observed that neuropeptide Y may be related to high levels of anxiety in atopic dermatitis at baseline.

UR - http://www.scopus.com/inward/record.url?scp=84855241634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855241634&partnerID=8YFLogxK

U2 - 10.2340/00015555-1189

DO - 10.2340/00015555-1189

M3 - Article

VL - 92

SP - 57

EP - 61

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 1

ER -